PSMD9 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL21943538	0.59	1/20
SCHEMBL21943762	0.57	1/20
SCHEMBL21944043	0.55	1/20
SCHEMBL21943004	0.55	1/20
SCHEMBL21942995	0.53	1/20
SCHEMBL21943411	0.53	1/20
SCHEMBL14042267	0.52	1/20
SCHEMBL21943429	0.52	1/20
SCHEMBL22066328	0.51	1/20
SCHEMBL21943540	0.49	1/20
SCHEMBL21943537	0.45	1/20
SCHEMBL24016281	0.44	1/20
SCHEMBL24532074	0.42	1/20
SCHEMBL1454562	0.42	1/20
SCHEMBL17612956	0.42	1/20
SCHEMBL12399198	0.42	1/20
SCHEMBL29911712	0.40	1/20

Clinical trials — most relevant to PSMD9 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease	PHASE4	UNKNOWN
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer	PHASE2	COMPLETED
Bortezomib in Treating Patients With Mantle Cell Lymphoma	PHASE2	COMPLETED
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma	PHASE2	WITHDRAWN
A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis	PHASE1/PHASE2	COMPLETED
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors	PHASE2	COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Biologic Correlative Taxotere/AC	PHASE2	COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma	PHASE1	COMPLETED
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer	PHASE1	COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM	PHASE1	WITHDRAWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Effect of Diaphragm Stimulation During Surgery	nan	COMPLETED
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Collection of Blood Samples for DNA in Motor Neuron Disease	nan	COMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS)	nan	UNKNOWN
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment	nan	UNKNOWN
Cardiovascular Complications of Carfilzomib Treatment	nan	UNKNOWN
Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia	nan	RECRUITING
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis	nan	UNKNOWN
Establishment of Human Cellular Disease Models for Wilson Disease	nan	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Quantitative Assessment of the Etiologies of Megalencephaly Associated With a Detectable Tumor Risk	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PSMD9 binder may also engage these)

Protein	Name	Similarity
Q3SZ19	—	1.000	Q3SZ19 →
Q9CR00	—	1.000	Q9CR00 →
Q9WTV5	—	1.000	Q9WTV5 →
F4HQD4	—	0.978	F4HQD4 →
Q804S5	—	0.976	Q804S5 →
Q99MP8	—	0.975	Q99MP8 →
B4F7E7	—	0.974	B4F7E7 →
Q9SRU7	—	0.974	Q9SRU7 →
Q6GNY1	—	0.974	Q6GNY1 →
Q803R5	—	0.973	Q803R5 →
Q921X6	—	0.973	Q921X6 →
Q9S7C0	—	0.973	Q9S7C0 →
Q80SY4	—	0.973	Q80SY4 →
O93257	—	0.972	O93257 →
Q2USD7	—	0.972	Q2USD7 →
Q86YT6	—	0.972	Q86YT6 →
Q8K339	—	0.972	Q8K339 →
P93648	—	0.972	P93648 →
A2YQ56	—	0.972	A2YQ56 →
Q9Y6D5	—	0.972	Q9Y6D5 →
BRAP	BRCA1-associated protein	0.972	landscape →
Q9VD25	—	0.971	Q9VD25 →
P54358	—	0.971	P54358 →
Q6WRS2	—	0.971	Q6WRS2 →
P51660	—	0.971	P51660 →
Q8TF65	—	0.971	Q8TF65 →
Q9UJA3	—	0.971	Q9UJA3 →
Q9ZVW2	—	0.971	Q9ZVW2 →
Q9CZU3	—	0.971	Q9CZU3 →
Q9VFS8	—	0.971	Q9VFS8 →